Dalteparin sodium injection
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Superficial Thrombophlebitis
Conditions
Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis
Trial Timeline
Oct 1, 2002 → Sep 1, 2011
NCT ID
NCT00264381About Dalteparin sodium injection
Dalteparin sodium injection is a approved stage product being developed by Pfizer for Superficial Thrombophlebitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00264381. Target conditions include Superficial Thrombophlebitis, Upper Extremity Superficial Thrombophlebitis, Lower Extremity Superficial Thrombophlebitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00264381 | Approved | Completed |
Competing Products
11 competing products in Superficial Thrombophlebitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| EG-70 (phase 1) + EG-70 (phase 2) | enGene | Phase 1/2 | 33 |
| Gemcitabine | Eli Lilly | Phase 2 | 52 |
| Gemcitabine + mitomycin C | Eli Lilly | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Diclofenac gel | Novartis | Approved | 85 |
| LDE225 0.75% + Vehicle | Novartis | Phase 2 | 52 |
| Rivaroxaban + Fondaparinux | Bayer | Phase 3 | 74 |
| Rivaroxaban + Placebo | Bayer | Phase 3 | 74 |
| Chemophase | Halozyme Therapeutics | Phase 1 | 30 |
| NDV-01 (sustained-release gemcitabine-docetaxel) | Relmada Therapeutics | Phase 3 | 69 |
| EscharEx 5% (EX-02 formulation) | MediWound | Phase 1/2 | 33 |